Annandale Capital’s AbbVie ABBV Stock Holding History

Annandale Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.1M	Buy	28,032 +12	+0%	+$2.66K	0.86%	34
2025 Q4	$6.4M	Sell	28,020 -702	-2%	-$160K	0.76%	36
2025 Q3	$66.5M	Sell	28,722 -338	-1%	-$68.8K	1.13%	26
2025 Q2	$5.39M	Sell	29,060 -80	-0.3%	-$14.9K	0.41%	34
2025 Q1	$6.11M	Hold	29,140	–	–	0.39%	35
2024 Q4	$5.18M	Buy	29,140 +34	+0.1%	+$6.25K	0.82%	35
2024 Q3	$5.75M	Hold	29,106	–	–	0.81%	30
2024 Q2	$4.99M	Buy	29,106 +25,406	+687%	+$4.21M	0.85%	29
2024 Q1	$674K	Hold	3,700	–	–	0.12%	84
2023 Q4	$573K	Hold	3,700	–	–	0.11%	91
2023 Q3	$552K	Hold	3,700	–	–	0.14%	80
2023 Q2	$499K	Sell	3,700 -65	-2%	-$9.53K	0.14%	87
2023 Q1	$600K	Hold	3,765	–	–	0.19%	79
2022 Q4	$608K	Sell	3,765 -377	-9%	-$57.8K	0.2%	80
2022 Q3	$556K	Sell	4,142 -35	-0.8%	-$5.02K	0.21%	80
2022 Q2	$640K	Hold	4,177	–	–	0.25%	68
2022 Q1	$677K	Hold	4,177	–	–	0.27%	66
2021 Q4	$566K	Hold	4,177	–	–	0.25%	70
2021 Q3	$451K	Hold	4,177	–	–	0.27%	58
2021 Q2	$470K	Sell	4,177 -2	-0%	-$225	0.28%	59
2021 Q1	$452K	Sell	4,179 -54	-1%	-$5.78K	0.32%	43
2020 Q4	$454K	Buy	+4,233	New	+$407K	0.38%	33

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Annandale Capital's ABBV Position: Q1 2026 in Review

Annandale Capital increased its AbbVie (ABBV) stake by 0.04% in Q1 2026, buying an estimated $2.66K and bringing the position to 28,032 shares worth $6.1M. The position accounts for 0.86% of the portfolio, ranked #34.

Annandale Capital first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $66.5M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Annandale Capital held 28,032 shares of AbbVie worth $6.1M as of Q1 2026.
Annandale Capital bought 12 AbbVie shares in Q1 2026, an estimated $2.66K.
AbbVie made up 0.86% of Annandale Capital's portfolio in Q1 2026, its #34 holding.
Annandale Capital first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
Annandale Capital's AbbVie position peaked at $66.5M in Q3 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Annandale Capital's 13F filing for Q1 2026, filed 15 May 2026.